# The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC

> **NIH NIH P41** · JOHNS HOPKINS UNIVERSITY · 2022 · $1,167,189

## Abstract

Overall – Summary
Research in immunology has created stunning scientific advances that have the potential to revolutionize
regenerative medicine, infectious disease, autoimmune disorders, neurodegenerative disease, and cancer.
Yet, innovations remain in the lab, not realizing their clinical potential. Immunologists develop therapies that
focus on fundamental mechanistic biology but lack tools to optimize therapies. Engineers bring a quantitative
approach and highly optimized devices and treatments, but often avoid the immune system entirely, rather
than trying to harness it. A profound gap exists between engineering and immunology, one that has held
back life-saving innovations from reaching the clinic.
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC will serve as a thought leader
and collaborative hub for immunoengineering research. JH-TIE will bring together the worlds of
engineering and immunology, leading the research and development of transformative cancer therapies and
regenerative medicine. JH-TIE's goals include:
 • Develop products, techniques, and methodologies to streamline the stimulation and expansion
 of functional T cells to provide a greater number of therapeutic cells faster and with greater
 proliferative potential, including a GMP-compliant batching methodology for scale-up;
 • Develop new enabling technologies, techniques, and products for more effective stimulation and
 modification of immune cells, including via biomaterials-based gene transfer and use of novel small
 molecule activators and inhibitors;
 • Develop new biotherapeutics for cellular engineering to increase T cell efficacy in vivo, including
 increased robustness of cytotoxic T cells against immunosuppressive counter-effects as well as
 complementary technology to engineer regulatory T cells for potential use for autoimmune diseases;
 • Expand the reach of immunoengineering principles by offering training courses, seminars, and
 curricula for researchers, industrial practitioners, clinicians, and students, including a new certificate
 program in immunoengineering for graduate students;
 • Advance the field of immunoengineering by hosting conferences, short courses, and other targeted
offerings;
 • Serve as an interface and liaison for communities of engineers, immunologists, and other
stakeholders.
Three Technology Research and Development (TR&D) projects that will serve as a foundation for the JH-TIE
center. Each TR&D is designed to deliver a technical service platform in support of a diverse community of end
users.
JH-TIE will provide training and dissemination of key technologies and techniques developed to collaborators
and the broader research community. Collaborative and service projects are proposed in conjunction with this
effort to broaden the technologies' impact. JH-TIE will expand on standard dissemination by hosting local
workshops and classes, international seminars, and web-based tutorials.
The JH-TIE will lead a paradigm shift an...

## Key facts

- **NIH application ID:** 10436868
- **Project number:** 5P41EB028239-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** JONATHAN P SCHNECK
- **Activity code:** P41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,167,189
- **Award type:** 5
- **Project period:** 2019-09-15 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10436868

## Citation

> US National Institutes of Health, RePORTER application 10436868, The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC (5P41EB028239-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10436868. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*